Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22734117 | 0.88 | KMT2A (0.34) | PDE10A | |
| SCHEMBL22734119 | 0.86 | TLR8 (0.37) | — | |
| SCHEMBL22734112 | 0.84 | ESR1 (0.40) | — | |
| SCHEMBL22734107 | 0.80 | GLP1R (0.33) | — | |
| SCHEMBL22734102 | 0.80 | GLP1R (0.33) | — | |
| SCHEMBL22734103 | 0.80 | GLP1R (0.33) | — | |
| SCHEMBL21074841 | 0.79 | LMNA (0.37) | LMNA | |
| SCHEMBL22734106 | 0.79 | GAA (0.37) | PDE10AADORA3ADORA1 | |
| SCHEMBL23084551 | 0.78 | — | — | |
| SCHEMBL31491356 | 0.77 | NSD2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3724195-B1 | SUBSTITUTED TETRAHYDROPYRAN DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION THERAPEUTICS AS (DK) | 2023-12-27 | — | — | EP | disclosed |
| US-11299497-B2 | Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | UNION therapeutics A/S (DK) | 2022-04-12 | — | — | US | disclosed |
| US-20200385400-A1 | SUBSTITUTED TETRAHYDROPYRAN DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299497-B2 | Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | PDE5A, PDE4A, PDE7A | LMNA 3148/4885PDE10A 33/4885ADORA3 1539/4885 |
| US-20200385400-A1 | SUBSTITUTED TETRAHYDROPYRAN DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE5A, PDE4A, PDE7A | LMNA 3148/4885PDE10A 33/4885ADORA3 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.